![Bernd Winterhalter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bernd Winterhalter
Corporate Officer/Principal bei
CureVac SE
Profil
Bernd Winterhalter is currently the Chief Development Officer at CureVac SE since 2019.
Prior to this, he worked as the Executive Medical Director at Bristol-Myers Squibb GmbH & Co. KGaA from 2004 to 2018 and as the Vice President-Medical, Science & Health Economics at Pharmacia GmbH from 1997 to 2003.
He also briefly served as the Chief Development Officer at CureVac NV from 2019 to 2021.
Dr. Winterhalter holds a doctorate degree from the University of Freiburg.
Aktive Positionen von Bernd Winterhalter
| Unternehmen | Position | Beginn |
|---|---|---|
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Corporate Officer/Principal | 01.12.2019 |
Ehemalige bekannte Positionen von Bernd Winterhalter
| Unternehmen | Position | Ende |
|---|---|---|
| CUREVAC | Corporate Officer/Principal | 01.02.2021 |
Bristol-Myers Squibb GmbH & Co. KGaA
 Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 |
Pharmacia GmbH | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
Ausbildung von Bernd Winterhalter
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
11
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
University of Freiburg
 University of Freiburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmacia GmbH | |
Bristol-Myers Squibb GmbH & Co. KGaA
Bristol-Myers Squibb GmbH & Co. KGaA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical medicines | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
